LRRK2 and Parkinson disease: Studies of astrocytes differentiated from LRRK2 G2019S PD iPSCs have reported lysosomal impairments, inflammation, and metabolomic changes [34,35,36], with no changes in glutamate uptake in the LRRK2 G2019S PD iPSC-differentiated astrocytes [35,37].